The use of immunoconjugates in cancer therapy

M. A. Ghetie, V. Ghetie, E. S. Vitetta

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Those immunoconjugates that have entered clinical trials (i.e., immunotoxins, radiolabelled and bispecific antibodies) have shown promising antitumour activity in haematopoietic tumours (lymphomas/leukaemias). To eliminate large solid tumours, immunoconjugates will require changes in both the antibody and effector moieties since these tumours are poorly vascularised and rarely express tumour-specific antigens. This review describes improvements which may have a major impact on the next generation of immunoconjugates.

Original languageEnglish (US)
Pages (from-to)309-321
Number of pages13
JournalExpert Opinion on Investigational Drugs
Volume5
Issue number3
StatePublished - 1996

Fingerprint

Immunoconjugates
Bispecific Antibodies
Immunotoxins
Neoplasms
Neoplasm Antigens
Lymphoma
Leukemia
Therapeutics
Clinical Trials
Antibodies

ASJC Scopus subject areas

  • Pharmacology

Cite this

The use of immunoconjugates in cancer therapy. / Ghetie, M. A.; Ghetie, V.; Vitetta, E. S.

In: Expert Opinion on Investigational Drugs, Vol. 5, No. 3, 1996, p. 309-321.

Research output: Contribution to journalArticle

Ghetie, M. A. ; Ghetie, V. ; Vitetta, E. S. / The use of immunoconjugates in cancer therapy. In: Expert Opinion on Investigational Drugs. 1996 ; Vol. 5, No. 3. pp. 309-321.
@article{1a1490179b90418598656587918608a4,
title = "The use of immunoconjugates in cancer therapy",
abstract = "Those immunoconjugates that have entered clinical trials (i.e., immunotoxins, radiolabelled and bispecific antibodies) have shown promising antitumour activity in haematopoietic tumours (lymphomas/leukaemias). To eliminate large solid tumours, immunoconjugates will require changes in both the antibody and effector moieties since these tumours are poorly vascularised and rarely express tumour-specific antigens. This review describes improvements which may have a major impact on the next generation of immunoconjugates.",
author = "Ghetie, {M. A.} and V. Ghetie and Vitetta, {E. S.}",
year = "1996",
language = "English (US)",
volume = "5",
pages = "309--321",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The use of immunoconjugates in cancer therapy

AU - Ghetie, M. A.

AU - Ghetie, V.

AU - Vitetta, E. S.

PY - 1996

Y1 - 1996

N2 - Those immunoconjugates that have entered clinical trials (i.e., immunotoxins, radiolabelled and bispecific antibodies) have shown promising antitumour activity in haematopoietic tumours (lymphomas/leukaemias). To eliminate large solid tumours, immunoconjugates will require changes in both the antibody and effector moieties since these tumours are poorly vascularised and rarely express tumour-specific antigens. This review describes improvements which may have a major impact on the next generation of immunoconjugates.

AB - Those immunoconjugates that have entered clinical trials (i.e., immunotoxins, radiolabelled and bispecific antibodies) have shown promising antitumour activity in haematopoietic tumours (lymphomas/leukaemias). To eliminate large solid tumours, immunoconjugates will require changes in both the antibody and effector moieties since these tumours are poorly vascularised and rarely express tumour-specific antigens. This review describes improvements which may have a major impact on the next generation of immunoconjugates.

UR - http://www.scopus.com/inward/record.url?scp=0029915723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029915723&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 309

EP - 321

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 3

ER -